- Home
- UCL vs CVM Comparison
UCL vs CVM Comparison
Compare UCL & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- CVM
- Stock Information
- Founded
- UCL 2014
- CVM 1983
- Country
- UCL Hong Kong
- CVM United States
- Employees
- UCL N/A
- CVM N/A
- Industry
- UCL Telecommunications Equipment
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UCL Consumer Discretionary
- CVM Health Care
- Exchange
- UCL Nasdaq
- CVM Nasdaq
- Market Cap
- UCL 48.7M
- CVM 40.1M
- IPO Year
- UCL 2020
- CVM 1987
- Fundamental
- Price
- UCL $1.32
- CVM $0.38
- Analyst Decision
- UCL
- CVM
- Analyst Count
- UCL 0
- CVM 0
- Target Price
- UCL N/A
- CVM N/A
- AVG Volume (30 Days)
- UCL 176.7K
- CVM 893.4K
- Earning Date
- UCL 03-13-2025
- CVM 01-13-2025
- Dividend Yield
- UCL N/A
- CVM N/A
- EPS Growth
- UCL 169.91
- CVM N/A
- EPS
- UCL 0.11
- CVM N/A
- Revenue
- UCL $87,405,000.00
- CVM N/A
- Revenue This Year
- UCL $7.02
- CVM N/A
- Revenue Next Year
- UCL $15.25
- CVM N/A
- P/E Ratio
- UCL $11.72
- CVM N/A
- Revenue Growth
- UCL 4.73
- CVM N/A
- 52 Week Low
- UCL $0.97
- CVM $0.36
- 52 Week High
- UCL $3.30
- CVM $3.08
- Technical
- Relative Strength Index (RSI)
- UCL 43.55
- CVM 41.52
- Support Level
- UCL $1.27
- CVM $0.36
- Resistance Level
- UCL $1.42
- CVM $0.45
- Average True Range (ATR)
- UCL 0.13
- CVM 0.03
- MACD
- UCL -0.01
- CVM 0.01
- Stochastic Oscillator
- UCL 9.77
- CVM 33.00
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc provides mobile data connectivity and portable WiFi services. The business operates under uCloudlink 1.0, which focuses on cross-border travelers that need mobile data connectivity services across different countries. Under uCloudlink 2.0, provides mobile data connectivity services to local users across different MNOs in a single country. It generates revenue from the provision of data connectivity services, and the sales of terminals and sales of data related products.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.